account adjust acquisition-rel cost certain
signific item
ep coupl penni forecast light revenu ep guidanc
ep ahead estim consensu
ep guidanc rais prior includ fx impact
approxim last publish ep estim
sale estim
consensu drug beat estim includ gardasil singulair
zostavax isentress cubicin combin forecast product
forecast includ vytorin zetia simponi januvia keytruda
remicad zepati combin light
anim sale forecast sale guidanc
narrow includ minim fx impact prior last
publish revenu estim
gpm estim
estim sg flat estim net non-oper
incom estim pre-tax margin
ahead estim tax rate estim share count
forecast
keytruda approv pdufa squamou nsclc w/
chemo pdufa merkel cell carcinoma pdufa eu
approv adjuv melanoma posit chmp oct regulatori file
 data neoadjuvant/adjuv tnbc tnbc
chl keytruda inlyta full data/regulatori file rcc met os/
lynparza w/azn regulatori file brcam ovarian cancer delstrigo/
pifeltro eu approv hiv posit chmp sept relebactem file w/imipenem
cilastin bacteri infect zerbaxa regulatori file vabp/habp
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market remicad zetia
vytorin cubicin nasonex biosimilars/gener competit pressur isentress
zostavax believ risk balanc opportun therefor remain market
perform stock
uptak keytruda nsclc
keytruda data readout variou tumor
keytruda approv sq
nsclc
lynparza file ovarian cancer
oper margin improv
keytruda data and/or uptak lung
posit expect
new product unabl off-set nasonex
vytorin/zetia cubicin patent
expir competit pressur
zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
cowen compani compani data
cowen compani
cowen compani
cowen compani
m-m-r ii cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock merck roch hold ltd adr secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
author report member author household long posit equiti secur merck
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
